I have re-read it (the Warren paper) and can see there are just enough nooks and crannies in the conclusion to justify GTCB taking another try at it. I hope the EMEA's "guidence" means they feel the same. Am I wrong or did one of your posts say Leo was putting up the money at least thru phase 2 ??
Do you know if the company has any interest in re opening the aborted trials involving by-pass surgery?? It seemed to me the indication was good and the trouble was with the surgeons who wanted to continue using Heparin along with Atrin. Six years have passed they might be more receptive.
Market Data 
Markets 
AI
